Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C11H23N2OS.O.V |
| Molecular Weight | 529.697 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | -4 |
SHOW SMILES / InChI
SMILES
[O--].[V].[H][C@](N)(C[S-])C(=O)NCCCCCCCC.[H][C@](N)(C[S-])C(=O)NCCCCCCCC
InChI
InChIKey=PTNIVTYIODVYLK-XFMZQWNHSA-L
InChI=1S/2C11H24N2OS.O.V/c2*1-2-3-4-5-6-7-8-13-11(14)10(12)9-15;;/h2*10,15H,2-9,12H2,1H3,(H,13,14);;/q;;-2;/p-2/t2*10-;;/m00../s1
Naglivan [PMD 501, vanadeine] is a vanadyl organometallic agent, in the preclinical phase of development in France, with Pan Medica, as an orally-active drug for the treatment of diabetes mellitus. Naglivan is an orally effective form of vanadyl with an oral potency 7.6 times greater than that of vanadyl sulfate (minimum effective dose: 0.06 mmol vanadium.kg-1.day-1) as compared to vanadyl sulfate (0.46 mmol vanadium.kg-1.day-1). The lack of incidence of diarrhea in either control or diabetic animals demonstrates that naglivan could be a more therapeutically desirable form of vanadyl.
Originator
Approval Year
Sample Use Guides
The antidiabetic effects of naglivan in rats made diabetic with streptozotocin (55 mg/kg, i.v.) were tested. Four days after the streptozotocin injection, one diabetic group (DVI) and a control group (CV) were treated with naglivan (50 mg/kg/day, equivalent to 0.06 mmol vanadium/kg/day) by oral gavage.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB09135MIG
Created by
admin on Sat Dec 16 08:29:49 GMT 2023 , Edited by admin on Sat Dec 16 08:29:49 GMT 2023
|
PRIMARY | |||
|
85E1SB2UXO
Created by
admin on Sat Dec 16 08:29:49 GMT 2023 , Edited by admin on Sat Dec 16 08:29:49 GMT 2023
|
PRIMARY | |||
|
100000084459
Created by
admin on Sat Dec 16 08:29:49 GMT 2023 , Edited by admin on Sat Dec 16 08:29:49 GMT 2023
|
PRIMARY | |||
|
C175155
Created by
admin on Sat Dec 16 08:29:49 GMT 2023 , Edited by admin on Sat Dec 16 08:29:49 GMT 2023
|
PRIMARY | |||
|
122575-28-4
Created by
admin on Sat Dec 16 08:29:49 GMT 2023 , Edited by admin on Sat Dec 16 08:29:49 GMT 2023
|
PRIMARY | |||
|
155491340
Created by
admin on Sat Dec 16 08:29:49 GMT 2023 , Edited by admin on Sat Dec 16 08:29:49 GMT 2023
|
PRIMARY | |||
|
DTXSID10153652
Created by
admin on Sat Dec 16 08:29:49 GMT 2023 , Edited by admin on Sat Dec 16 08:29:49 GMT 2023
|
PRIMARY | |||
|
6789
Created by
admin on Sat Dec 16 08:29:49 GMT 2023 , Edited by admin on Sat Dec 16 08:29:49 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
